DrugsControl Media Services

News Detail

SEC recommends permission for phase I trial of Cadila Pharma's VZV vaccine (22-09-2023)

New Delhi, 22 Sept 2023: The Subject Expert Committee (SEC) on vaccines, which reviews proposals and advice the Drugs Controller General (India) (DCGI) in matters for biologicals and post approval change proposals, has recommended to grant permission to Gujarat-based Cadila Pharm......
View Details

Source : Pharmabiz
Subject Expert Committee SEC DCGI biological Cadila Pharmaceuticals Varicella-Zoster Virus VZV vaccine New Drugs and Clinical Trials Rules 2019 WHO Varicella chickenpox varicella-zoster virus herpesvirus Oka VZV MMRV ThRabis

Related News